Skip to main content
| News

Versant Ventures establishes Vector BioPharma AG

12.08.2022

Vector Biopharma is the latest company to be founded by Ridgeline, a discovery engine from Basel-based venture capitalist Versant Ventures. Vector develops a platform for the targeted administration of high-capacity genetic payloads.

biotech

Versant Ventures has announced the founding of Vector BioPharma AG. The new company is being launched out of the Ridgeline discovery engine from globally active investor Versant Ventures. The venture capitalist for biotech companies provided startup funding amounting to 30 million US dollars. In addition to Versant Ventures, the University of Zurich (UZH) is also a partner of Vector.

Vector develops a platform for the targeted administration of high-capacity genetic payloads. According to a press release from Versant Ventures, this is able to overcome the three main obstacles that face other technologies: issues with tissue-specific delivery of payloads, limitations on the size of genetic cargo that can be packaged, and adverse immunogenic reactions.

Platform with advantages

Vector CEO Lorenz Mayr states that the platform has “significant advantages” as a result of its abilities regarding these obstacles. He adds that the technology has the potential to change the safety, efficacy, and specificity of biologics and gene and cell therapies.

Andreas Plückthun from the University of Zurich adds: “It is gratifying to see the work that started 10 years ago is now being translated into new therapies.” He developed this platform as a pioneer in the field of protein engineering. Plückthun is a Co-Founder of Vector and is a member of the board.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.